Trial · NCT03732807
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Participants with missing SALT scores due to coronavirus disease-19 related reasons were excluded from this analysis, while participants with missing data due to other reasons were considered as non-responders. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Analysis 4: Data imputed by using a missing at random (MAR) mechanism for participants with missing data due to COVID-19. Missing data due to reasons not related to COVID-19 were consider as non-responders. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Analysis 1: Participants with missing SALT score at Week 24 due to COVID-19 related reasons excluded from analysis at that time point, participants with missing SALT scores due to other reasons counted as non-responders at that time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24 | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model | Week 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48 | Week 4, 8, 12, 18, 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48 | Week 4, 8, 12, 18, 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24 | Baseline (Day 1), Week 4, 8, 12, 18, and 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in SALT Score at Week 28, 34, 40, and 48 | Baseline (Day 1), Week 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Units on a scale | MEAN |
| SECONDARY | Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | Week 4, 8, 12, 18, 24, 28, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48 | Week 4, 8, 12, 18, 24, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations | Baseline (Day 1), Week 4, 8, 12, 18, and 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations | Baseline (Day 1), Week 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point. | Units on a scale | MEAN |
| SECONDARY | Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48 | Week 4, 8, 12, 18, 24, 34, 40, and 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specified time point. | Percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24 | Baseline (Day 1), Week 4, 8, 12, and 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Units on a scale | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48 | Baseline (Day 1), Week 48 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Units on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24 | Baseline (Day 1), Week 4, 8, 12, and 24 | FAS included all participants who were randomized, regardless of whether they received study medication. Here, number analyzed signifies participants evaluable at specific time point. | Units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03732807/outcomes